DOJ Schedules Three Kratom-Derived Opioid Compounds, Leaves Botanical Leaf Untouched

Why it matters

The federal action draws a formal line between traditional kratom leaf and highly concentrated synthetic derivatives, but a Texas wrongful-death case suggests that line may be harder to enforce than regulators expect.

The big picture

The move follows a broader federal push against potent kratom derivatives, including the DEA's separate effort to schedule 7-hydroxymitragynine. Industry groups are split between traditional 'pure leaf' sellers and companies marketing more potent, chemically altered products, and litigation is starting to surface lab results that complicate the industry's safety claims.

Key findings

• DOJ temporarily placed mitragynine pseudoindoxyl (MGPI), MGM-15 and MGM-16 into Schedule I of the Controlled Substances Act
• Attorney General Todd Blanche said the action targets "deliberately manufactured and concentrated opioid products, not traditional botanical kratom"
• DOJ will use enforcement discretion when only incidental trace amounts of MGPI appear in otherwise botanical kratom products
• MGPI has been measured as up to 20 times stronger than morphine
• A Texas wrongful-death lawsuit found MGPI in multiple "pure leaf" products from a major kratom brand, undercutting the clean leaf-versus-synthetic distinction

What they say

"The Justice Department is acting before these dangerous compounds become a broader threat," Attorney General Todd Blanche said. Attorney Talis Abolins, who has litigated wrongful-death cases against kratom producers, said lab testing found MGPI across supposedly pure-leaf products: "Did they know all along?"

Bottom line

**Federal scheduling of three synthetic kratom derivatives leaves the botanical leaf legal for now, but emerging lab evidence suggests the leaf-versus-synthetic distinction the policy relies on may not hold up.**